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Targeted delivery represents a promising approach for the devel-
opment of safer and more effective therapeutics for oncology
applications. Although macromolecules accumulate nonspecifically
in tumors through the enhanced permeability and retention (EPR)
effect, previous studies using nanoparticles to deliver chemother-
apeutics or siRNA demonstrated that attachment of cell-specific
targeting ligands to the surface of nanoparticles leads to enhanced
potency relative to nontargeted formulations. Here, we use
positron emission tomography (PET) and bioluminescent imaging
to quantify the in vivo biodistribution and function of nanopar-
ticles formed with cyclodextrin-containing polycations and siRNA.
Conjugation of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid to the 5 end of the siRNA molecules allows labeling with 64Cu
for PET imaging. Bioluminescent imaging of mice bearing lucif-
erase-expressing Neuro2A s.c. tumors before and after PET imaging
enables correlation of functional efficacy with biodistribution data.
Although both nontargeted and transferrin-targeted siRNA nano-
particles exhibit similar biodistribution and tumor localization by
PET, transferrin-targeted siRNA nanoparticles reduce tumor lucif-
erase activity by 50% relative to nontargeted siRNA nanopar-
ticles 1 d after injection. Compartmental modeling is used to show
that the primary advantage of targeted nanoparticles is associated
with processes involved in cellular uptake in tumor cells rather than
overall tumor localization. Optimization of internalization may
therefore be key for the development of effective nanoparticle-
based targeted therapeutics.
kinetic modeling  multimodality imaging  targeted delivery 
tumor uptake
Targeted nanoparticles are a promising class of new experimentalmedicines that have the potential to provide increased efficacy
and lower toxicity relative to conventional therapeutics. Through
the enhanced permeability and retention (EPR) effect, macromo-
lecular therapeutics tend to accumulate within tumors after sys-
temic delivery (1). As such, nanoparticles represent an approach for
the delivery of large drug payloads to tumors. However, because
many drugs require cellular internalization for efficacy, accumula-
tion within the tumormicroenvironment by the EPR effectmay not
correlate with therapeutic outcome.
siRNA molecules are short double-stranded nucleic acid mole-
cules that can act as mediators of RNAi within the cytoplasm of a
cell. Therapeutic application of siRNAs requires their effective
delivery into the target cells of interest, because naked siRNAs do
not enter most cell types on their own. To address the challenge of
nucleic acid delivery, a variety of methodologies have been devel-
oped with varying success, including covalent attachment of cho-
lesterol, interaction with antibody-protamine fusion proteins, lipo-
some encapsulation, or nanoparticle formation with cationic lipids
or polymers (2–6).
Targeted delivery approaches involve the use of cell-specific
targeting ligands that can bind to surface receptors on cells.
Recent reports have highlighted the importance of these target-
ing ligands for efficacy when delivering a variety of payloads
(7–10). For example, anti-HER2 immunoliposomes containing
doxorubicin achieved greater antitumor efficacy relative to
nontargeted liposomes in HER2-overexpressing human breast
cancer xenografts, but this difference in antitumor efficacy was
not observed in non-HER2-overexpressing tumor xenografts
(9). Additionally, transferrin (Tf)-targeted nanoparticles formed
by using cyclodextrin-containing polycations and siRNA led to
significant inhibition of tumor growth in a disseminated model
of Ewing’s sarcoma, whereas an identical nanoparticle formu-
lation without Tf did not lead to such tumor growth inhibition
(10). This result is consistent with two previous reports using this
system to deliver plasmid DNA¶ and a DNAzyme (11) that
showed that the amount of nucleic acid reaching tumors did not
depend on the presence of Tf, but plasmid expression¶ and
intracellular localization within tumor cells (11) occurred only
with the Tf-targeted nanoparticles.
Although targeted nanoparticles appear to display enhanced
potency relative to nontargeted nanoparticles, this is not necessarily
a result of increased tumor uptake. Kirpotin et al. (12) established
that attachment of antibody targeting ligands to long-circulating
nanoparticles increases cellular internalization without affecting
overall tumor uptake. This behavior may be unexpected because
the targeting ligands alone do show enhanced uptake within tumors
expressing the relevant antigen (13). Relatively few studies have
attempted to address how the pharmacokinetics and biodistribution
of nanoparticles are affected by attachment of targeting ligands, yet
such studies will be critical for designing more effective nanopar-
ticle carriers. Medarova et al. (14) described the use of MRI and
fluorescence imaging to monitor the local tumor accumulation and
functional activity of magnetic nanoparticles covalently linked to
siRNAs. That study illustrated the power of using multimodality
imaging approaches to correlate localization of therapeutic entities
to their biological activity.
Here, we employ positron emission tomography (PET)/
computer tomography (CT) to monitor whole-body biodistribution
kinetics and tumor localization of siRNA nanoparticles while
Author contributions: D.W.B., H.S., W.A.W., and M.E.D. designed research; D.W.B., H.S.,
and I.J.H. performed research; D.W.B., H.S., W.A.W., and M.E.D. analyzed data; and D.W.B.
wrote the paper.
Conflict of interest statement: M.E.D. is a consultant to and has stock in Calando
Pharmaceuticals.
Freely available online through the PNAS open access option.
Abbreviations: BLI, bioluminescent imaging; CT, computer tomography; DOTA, 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid; EPR, enhanced permeability and reten-
tion; ID, injected dose; PET, positron emission tomography; Tf, transferrin.
§To whom correspondence should be addressed. E-mail: mdavis@cheme.caltech.edu.
¶Bellocq, N. C., Davis, M. E., Engler, H., Jensen, G. S., Liu, A., Machemer, T., Maneval, D. C.,
Quijano, E., Pun, S. H., Schluep, T., Wen, S. (2003) Mol Ther 7:S290 (abstr.).
This article contains supporting information online at www.pnas.org/cgi/content/full/
0707461104/DC1.
© 2007 by The National Academy of Sciences of the USA









concurrently using bioluminescent imaging (BLI) to measure lu-
ciferase knockdown by the delivered siRNA molecules. By formu-
lating nanoparticles with or without Tf targeting ligands, the effect
of cell-specific targeting on both biodistribution and function can be
studied simultaneously within the same animal. A mathematical
model of targeted nanoparticle behavior is presented that can
describe the results obtained here and illustrate concepts that can
be applied generally to the design of targeted therapeutics for
oncology applications.
Results
Formation of 64Cu-Labeled Nanoparticles, Using 1,4,7,10-
Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid (DOTA)-siRNA.
DOTA was conjugated to the 5 end of an siRNA sequence
targeting luciferase mRNA. A nonradioactive assay, using gad-
olinium, demonstrated that the DOTA-siRNA was able to bind
gadolinium, and this binding efficiency was 50% of that
observed for free DOTA. The DOTA-siRNA retained its func-
tional capacity to silence luciferase expression, albeit at a slightly
reduced potency relative to unmodified siRNA [supporting
information (SI) Fig. 5]. Furthermore, the duration of luciferase
knockdown is consistent with an RNAi-based mechanism (15,
16). Nanoparticles were successfully formed with DOTA-
siRNA, and the fraction of the total siRNA that was modified
with DOTA had a negligible effect on nanoparticle zeta poten-
tial and only a minor effect on nanoparticle size (SI Fig. 6).
Nanoparticles formed with either unmodified siRNA or with
DOTA-siRNA representing 20% or 50% of the total siRNA
demonstrated equivalent stability against nuclease degradation
of the encapsulated siRNA after incubation in mouse serumwith
an estimated half-life of 11 h (SI Fig. 7).
Biodistribution of Naked siRNA and siRNA Nanoparticles After i.v.
Administration.Micro-PET/CT was used to examine the kinetics of
the biodistribution and tumor localization of 64Cu-labeled mole-
cules after i.v. injection in mice. Reconstructed micro-PET/CT
images of mice at 1, 10, and 60 min after injection are shown in SI
Fig. 8. Images were quantified by using AMIDE software, and the
percentage of injected dose (ID)/cm3 was calculated for each region
of interest over all time frames (17). The resulting time–activity
curves shown in Fig. 1 represent the averages from two (64Cu,
64Cu-DOTA) or three (64Cu-DOTA-siRNA, Tf-targeted nanopar-
ticles) independent experiments. SI Fig. 9 contains these same
time–activity curves plotted with different scales.
64Cu alone accumulated rapidly in the liver, plateauing at25%
ID/cm3 after only 10 min, likely resulting from binding to serum
proteins (18). However, when the 64Cu was chelated by DOTA and
injected systemically in mice, it accumulated in the kidneys (57%
ID/cm3 at 60 min) and bladder (91% ID/cm3 at 60 min) with very
little in the liver (5%ID/cm3 at 60min), consistentwith the kidney
clearance of other metal chelators, such as diethylenetriaminepen-
taacetic acid (19). When the DOTA was conjugated to an siRNA
molecule and labeled with 64Cu (64Cu-DOTA-siRNA), the ob-
served biodistribution kinetics were characterized by rapid blood
clearance through liver accumulation (23% ID/cm3 at 60 min)
and kidney filtration into the bladder (73% ID/cm3 at 60 min).
The total siRNAadministered permousewas 2.5mg/kg, and50%
of this siRNA was 64Cu-DOTA-siRNA (purified by ethanol pre-
cipitation). A biexponential fit of the 64Cu-DOTA-siRNA plasma
concentration yielded an initial elimination half-life of 2.4 min and
a terminal elimination half-life of 61.9 min. The rapid initial
elimination half-life is expected for siRNA molecules whose small
size (13 kDa) allows first-pass renal clearance, and these results,
using micro-PET, are consistent with values reported in refs. 2, 20,
and 21.
Micro-PET/CT was also used to examine the kinetics of the
biodistribution and tumor localization of siRNAnanoparticles after
i.v. injection in mice. The total dose of siRNA within the nanopar-
ticles was the same as that used for naked siRNA (2.5 mg/kg), and
again 50% of the total siRNA was DOTA-siRNA. The biodis-
tribution of the 64Cu-DOTA-siRNA packaged into Tf-targeted
nanoparticles appeared similar to that observed for naked 64Cu-
Fig. 1. Average time–activity curves for the first 60 min after injection. Data are shown for mice injected with 64Cu (A), 64Cu-labeled DOTA (B), 64Cu-labeled
DOTA-siRNA (C), and Tf-targeted nanoparticles containing 64Cu-labeled DOTA-siRNA (D). Error bars indicate SE.
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DOTA-siRNA, except that there was slightly higher liver accumu-
lation (26% ID/cm3 at 60 min) and a delayed peak in kidney
accumulation (10 min after injection). Although liver uptake is
often observed for nanoparticles because of interactions with the
reticuloendothelial system, the lack of significant lung-associated
activity suggests that PEGylation and Tf targeting may shield the
positively charged nanoparticles and reduce nonspecific interac-
tions (7, 8, 11, 22). These observations are also consistent with those
reported by de Wolf et al. (23), who noted that formulation of the
siRNA into polycationic carriers had little effect on the pharma-
cokinetics and initial tumor localization compared with naked
siRNA; both naked siRNA and siRNA packaged into the carriers
exhibited rapid blood clearance with tissue distribution mainly to
the kidneys and liver within the first 15 min after injection.
The significant portion of the activity after injection of Tf-
targeted nanoparticles that cleared rapidly through the kidneys and
was excreted in the urine suggests that free siRNA may have been
present, because intact nanoparticles are too large for kidney
filtration into the urine. However, the nanoparticle formulations
showed 10% free siRNA when analyzed by gel electrophoresis
immediately before injection (SI Fig. 10). Therefore, it is possible
that nanoparticle disruption and release of free siRNA after
injection into the bloodstream may contribute to the similar phar-
macokinetics observed for naked siRNA and siRNA nanoparticles.
Because the nanoparticles are formed through electrostatic inter-
actions, competition from electrolytes, polyanions, or polycations
present within the bloodstream may destabilize the nanoparticles.
No free siRNA was detected by gel electrophoresis after exposure
of targeted nanoparticles to fresh mouse blood for 5 min (SI Fig.
11). However, contact of siRNA nanoparticles to increasing con-
centrations of NaCl did release free siRNA, with 50% dissocia-
tion at 0.4 M NaCl (SI Fig. 12). SI Text contains one hypothesis for
a physiologically based mechanism that could contribute to the
NaCl-mediated disruption of the nanoparticles within the kidneys.
However, because the imaging methodology used here does not
differentiate between intact/degraded forms of the nanoparticles or
siRNAmolecules, it remains unknown as to exactly how and inwhat
form the 64Cu gets into the urine (SI Fig. 13).
Tumor Localization and Function of Targeted Versus Nontargeted
siRNA Nanoparticles.Amultimodality imaging approachwas used to
investigate the biodistribution and functional activity of siRNA
delivered by Tf-targeted or nontargeted nanoparticles. Micro-
PET/CT permitted analysis of the biodistribution and tumor local-
ization of the siRNA nanoparticles, whereas BLI enabled quanti-
fication of the resulting luciferase knockdown by siRNA.
Initial studies, using micro-PET/CT, revealed that the tissue
distribution of the 64Cu-DOTA-siRNA delivered by Tf-targeted
and nontargeted nanoparticles was very similar for the first hour
after injection, with similar blood clearance and tumor accumula-
tion (Fig. 2). The combination of micro-PET/CT and BLI provided
additional insights into the effect of the Tf targeting ligands, and
Fig. 3 contains the micro-PET/CT images (1 d after injection) and
corresponding bioluminescent images (before injection and 1 d
after injection) of two representative mice. The average tumor
activities at 1 d after injection measured by micro-PET were 1.1
0.3% ID/cm3 and 1.4  0.4% ID/cm3 for Tf-targeted and nontar-
geted nanoparticles, respectively. These same mice were also ex-
amined for luciferase activity by BLI before injection and 1 d after
injection. The relative increase in tumor luciferase activity in mice
treated with Tf-targeted nanoparticles was 50% lower than that in
mice treated with nontargeted nanoparticles (Fig. 3C). These data
provide strong evidence suggesting that Tf-targeted nanoparticles
were able to deliver more functional siRNA into the tumor cells
than nontargeted nanoparticles, even though both accumulated to
a similar extent within the tumor microenvironment.
Compartmental Model Analysis of Tumor Localization and Uptake.
Compartmental modeling provides insights into the impact that
tumor-specific targeting can have on the tumor localization of
systemically applied therapeutics (Fig. 4). The first term in the
equation for tumor uptake (‘‘Total’’ in Fig. 4A) represents the
contribution from the tumor vascular space during the wash-in
phase, and a rate constant of 25 min1 is used to estimate the early
peak after injection. A reasonable fit for targeted nanoparticle
tumor uptake can be achieved if k21  0. Under these conditions,
a two-compartment model with k23  0 yields the same curve for
Total as a three-compartment model with a nonzero value for k23
(Fig. 4B). Targeting ligands that can enhance tumor-specific bind-
ing (k23) are not expected to increase overall tumor uptake (C2 
C3) for entities that remain trapped in the tumormicroenvironment
and do not reversibly return to the blood circulation. However,
simulations also show that for entities that can rapidly exchange
between the blood compartment and the tumor interstitial space,
tumor-specific targeting can significantly improve tumor uptake.
These generalizable trends are illustrated in Fig. 4C. Consistent
with these simulations, Adams et al. (24) demonstrated that an scFv
(Mr 25,000) against HER2/neu exhibited 7-fold greater tumor
accumulation than an anti-HER2/neu scFv with a 320-fold lower
affinity. Conceptually, tumor-specific binding reduces the amount
of freematerial that would otherwise be available for exchangewith
the blood compartment. This decrease in C2 has the same conse-
quence of enhanced tumor accumulation as a decrease in k21 caused
by the EPR effect when the tumor uptake is measured as the total
amount present (intracellular  extracellular) in the tumor micro-
environment, as is done with micro-PET.
Discussion
This study demonstrates the utility of noninvasive imaging tech-
nologies to concurrently investigate the impact of cell-specific
Fig. 2. Tissue distribution of 64Cu-DOTA-siRNA delivered by targeted (Tf) and
nontargeted (PEG) nanoparticles. (A) Fused micro-PET/CT images of mice at 1,
10, and 60 min after injection. (B) Blood clearance and tumor localization of
Tf-targeted and nontargeted siRNA nanoparticles.









targeting ligands on the biodistribution and function of targeted
siRNA nanoparticles in vivo. Synthesis of DOTA-conjugated
siRNA molecules enables labeling with 64Cu and subsequent im-
aging by micro-PET, which provides high-resolution, three-
dimensional biodistribution data of the injected radiolabeled mol-
ecules over time. The spatiotemporal distribution of the injected
64Cu-labeled molecules was determined by coregistration of the
micro-PET images with anatomical information from micro-CT.
Furthermore, BLI was used to measure the relative change in
luciferase activity resulting from siRNA function within the tumor
cells. This methodology enables investigation of the differences in
biodistribution and functional efficacy between targeted and non-
targeted siRNA nanoparticles.
Attachment of the Tf targeting ligand to the surface of the
nanoparticles has a negligible impact on the biodistribution ob-
served bymicro-PET. Both targeted and nontargeted nanoparticles
demonstrate nearly identical tumor localization kinetics and at 1 d
after injection show similar tumor accumulation (1% ID/cm3).
This is likely a consequence of the EPR effect, which traps
macromolecules in the tumor microenvironment. Using the same
delivery system carrying plasmid DNA or a DNAzyme, tumor
accumulation is shown to be mouse-model-dependent and can
reach 10% ID. Although the accumulated amounts vary with
tumor type, they are not correlated to the Tf receptor status of the
tumor cells (11).
BLI was used to examine function in tandem with the tissue
distribution studies by micro-PET. Unlike the micro-PET results
showing that the tissue distribution is approximately equal for both
targeted and nontargeted nanoparticles, BLI reveals that targeted
nanoparticles more effectively reduce tumor luciferase expression
1 d after injection. These results likely indicate that a higher fraction
of the siRNA achieves intracellular localization and thereby func-
tional activity within the tumor cells when delivered by using
Tf-targeted nanoparticles. Previous studies with other targeted
delivery systems have also suggested that the targeting moieties do
not necessarily increase the total tumor accumulation but instead
contribute to enhanced internalization by the tumor cells (9, 12, 25).
Fig. 3. Multimodality in vivo imaging of siRNA nanoparticle delivery and
function, using micro-PET/CT and BLI. (A) Fused micro-PET/CT images showing
tumor-associated (arrow) activity 1 d after injection of targeted (Tf) and
nontargeted (PEG) nanoparticles containing 64Cu-DOTA-siRNA. (B) BLI of the
same mice shown in A before injection and 1 d after injection. (C) Relative
change in luciferase expression 1 d after injection of Tf-targeted (Tf,n7) and
nontargeted (PEG, n  4) nanoparticles containing 64Cu-DOTA-siRNA for
simultaneous PET imaging. Error bars indicate SE.
Fig. 4. Analysis of the interplay between the EPR effect and tumor-specific
targeting, using a three-compartment model. (A) Model schematic and gov-
erning equations to estimate tumor uptake. (B) Model fit for total tumor
uptake (Total) from experimental data (Exp) in Fig. 2, using k21  k23  0. C2
is the concentration in compartment 2. (C) Effect of tumor clearance (k21) and
tumor-specific binding/uptake (k23) on tumor accumulation 1 d after injection.
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This study therefore highlights the potentially important differ-
ence in the relative distribution between intracellular and extracel-
lular tumor space for targeted andnontargeted entities.Nonspecific
tumor accumulation (e.g., the EPR effect) can dominate for
sufficiently large macromolecular entities, such as nanoparticles,
whereas specific interaction between targeting ligands and tumor
cells can drive tumor accumulation for relatively small molecules.
Moreover, the physicochemical properties of nanoparticle carriers
will largely determine their pharmacokinetics/biodistribution, but
the presence of targeting ligands can greatly enhance intracellular
uptake. Such considerations will be important for the design of
molecular conjugates for imaging and therapeutic applications in
oncology.
Materials and Methods
siRNA Sequence. RNA oligonucleotides were ordered from Inte-
grated DNA Technologies (Coralville, IA). For the siRNA duplex
against luciferase, the antisense strand (5-UAUCGAAGGACU-
CUGGCACdTdT-3) was ordered unmodified, whereas the sense
strand (5-GUGCCAGAGUCCUUCGAUAdTdT-3) was or-
dered unmodified or with a 5 amino modifier C6 modification on
the 5 endof the sense strand.Anontargeting control siRNAduplex
was created by using unmodified versions of both the antisense
(5-UAGCGACUAAACACAUCAAUU-3) and sense (5-
UUGAUGUGUUUAGUCGCUAUU-3) strands.
Synthesis of DOTA-siRNA. 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid mono(N-hydroxysuccinimide ester) (DOTA-NHS-
ester) was ordered from Macrocyclics (Dallas, TX). The amine-
modified RNA sense strand with a 100-fold molar excess of
DOTA-NHS-ester in carbonate buffer (pH 9) was added to a
microcentrifuge tube. The contents were reacted by stirring for4
h at room temperature. The DOTA-RNAsense conjugate was
ethanol-precipitated, resuspended in water, and annealed to the
unmodified antisense strand to yield DOTA-siRNA. All liquids
were pretreated with Chelex-100 (Bio-Rad, Hercules, CA) to
remove trace metal contaminants.
Verification of DOTA-siRNA Conjugation. Equimolar amounts of
gadolinium chloride (GdCl3) and either DOTA or DOTA-siRNA
in 0.1 M ammonium acetate buffer (pH 6) were added to a
microcentrifuge tube. The microcentrifuge tubes were incubated
for 15 min at 75°C for the labeling reaction. Half of the labeling
reaction was combined with an equal volume of 1 mM arsenazo III,
and the absorbance at 660 nm was measured by using a Safire plate
reader (Tecan,Durham,NC). The presence of free gadolinium ions
results in a bathochromic shift from 548 nm to 660 nm, and
comparisonwith a standard curve allowed estimation of the amount
of free gadolinium remaining.
In Vitro Transfection.Neuro2A-Luc cells with constitutive luciferase
expression were transfected with siRNA by using Oligofectamine
(Invitrogen, Carlsbad, CA), and the kinetics of the luciferase
knockdown by unmodified and DOTA-conjugated siRNA were
determined by using the Xenogen (Alameda, CA) IVIS 100 as
described in refs. 15 and 16.
64Cu Labeling. 64Cu chloride was produced at Washington Univer-
sity (St. Louis, MO). The 64Cu chloride was mixed with citrate
buffer (pH 5, 0.1 M), and DOTA or DOTA-siRNA was added to
achieve a final DOTA:64Cu ratio of 250:1. The mixture was incu-
bated for 1 h at 60°C, and the DOTA-siRNA labeling reaction was
purified by gel filtration or ethanol precipitation. Gel filtration was
performed by using MicroSpin G-25 columns (Amersham Bio-
sciences, Little Chalfont, U.K.) according to manufacturer’s in-
structions. Ethanol precipitation was accomplished by adding 0.1
vol of 3M sodium acetate and 2.5 vol of prechilled ethanol followed
by incubation for 2 h at 80°C. The precipitated DOTA-siRNA
was centrifuged, washed with 70% ethanol, and resuspended in
water to yield 64Cu-DOTA-siRNA.
Nanoparticle Formation. Tf-targeted and nontargeted siRNA nano-
particles were formed by using cyclodextrin-containing polycations
as described in ref. 6. Typically, nanoparticles were formed in water
at a charge ratio of 3 (/) and an siRNA concentration of 0.5
g/liter. One percent of the adamantane-PEG molecules on the
surface of the targeted nanoparticles were modified with Tf (ada-
mantane-PEG-Tf). The nanoparticles were suspended in a 5%
(wt/vol) glucose carrier solution for injection.
Dynamic Light Scattering. Nanoparticles were formed in water at a
charge ratio of 3 (/) and an siRNA concentration of 0.1 g/liter.
A ZetaPALS instrument (Brookhaven Instruments, Holtsville,
NY) was used to measure both the effective hydrodynamic diam-
eter and zeta potential.
Serum Stability of siRNA Nanoparticles. Tf-targeted nanoparticles
were incubated in 50%mouse serum (Sigma, St. Louis,MO) for 4 h
at 37°C and 5% CO2. Aliquots were removed at specified time
points and run on an agarose gel to determine the amount of intact
Table 1. Model variables
Name Compartment Description (units)
C1 1, plasma Plasma concentration (mol L1)
C2 2, interstitial (tumor) Interstitial concentration (mol L1)
C3 3, cell-associated or intracellular (tumor) Tumor cell-associated concentration (mol L1)
Table 2. Model parameters
Name Description (units) Determination Value
k12 Extravasation (min1) Fit to data 3.1  104
k21 Return to blood (min1) Varied
k23 Binding to or uptake by tumor cells (min1) Varied
k32 Release from binding (min1) Estimated from ref. 27, mAb/TfR 7  103
kelim Rate of elimination from blood (min1) Estimated from data in Fig. 2 0.14
V1 Plasma volume, mouse (L) Estimated from ref. 28 1.5  103
V2 Tumor interstitial volume (L) Estimated from ref. 29, 300 mm3 tumor 1.1  104
V3 Tumor cellular volume (L) Estimated from ref. 29, 300 mm3 tumor 1.8  104
Vtv Tumor vascular volume (L) Estimated from ref. 29, 300 mm3 tumor 1.5  105









siRNA remaining. Nanoparticles incubated in water instead of
mouse serum served as controls. Dissociation of the nanoparticles
was achieved by adding 1% SDS immediately before gel loading.
siRNA bands were visualized by ethidium bromide staining and
quantified by using ImageJ software.
Salt Stability of siRNA and pDNA Nanoparticles. Tf-targeted nano-
particles were formed in water at a charge ratio of 3 (/) and an
siRNA or pDNA concentration of 0.5 g/liter. A portion of the
nanoparticle formulation (containing 1g of siRNAor pDNA)was
added to a microcentrifuge tube and mixed with 1% SDS or NaCl
at a range of concentrations from 0 to 1.5 M NaCl. The samples
were allowed to incubate for 3–5 min at room temperature before
being loaded into a 1% agarose gel. Bands were visualized by
ethidium bromide staining, and quantification of intact siRNA or
pDNA nanoparticles (bands remaining in the well at the top of the
gel) was performed by using ImageJ software.
Animals and Tumor Formation. Severe combined immunodeficient
(NOD/SCID) mice were purchased from The Jackson Laboratory
(Bar Harbor, ME). All animal manipulations were performed with
sterile technique and were approved by theUniversity of California
at Los Angeles Animal Research Committee. Neuro2A-Luc cells
were cultured in DMEM supplemented with 10% FBS, 2 mg/ml
glucose, 100 units/ml penicillin, and 100 units/ml streptomycin.
Exponentially growing Neuro2A-Luc cells were removed from the
plate with trypsin, resuspended in PBS and Matrigel (BD Bio-
sciences, San Jose, CA), and injected s.c. into the right flank of
NOD/SCID mice at 1–2  106 cells per mouse. Tumors were
allowed to grow to 6–7 mm in diameter before injection and
imaging.
Micro-PET/CT Imaging.Micro-PET/CT imaging was performed with
a micro-PET FOCUS 220 PET scanner (Siemens, Malvern, PA)
and a MicroCAT II CT scanner (Siemens) (23). Fifteen minutes
before imaging, mice were anesthetized by using 1.5–2% isoflurane
in a heated (30°C) induction chamber, then transferred to a heated
isolation/imaging chamber. 64Cu (100–300 Ci) (1 Ci  37 GBq)
was injected via tail vein while the anesthetized animals were
positioned on the scanner bed, and a dynamic PET scan was
acquired for 1 h. Mice were moved to the micro-CT in the same
isolation/imaging chamber (26). PET images were reconstructed by
filtered back projection, using a ramp filter to yield an image
resolution of 1.7 mm. Immediately after the micro-PET scan, mice
underwent a 7-min micro-CT scan, using routine image acquisition
parameters (26). The micro-CT scan was used for anatomical
localization of the tissue concentrations of the 64Cu over time by
micro-PET. Static micro-PET scans were acquired on the following
day (18–24 h after injection) with another micro-CT scan for
anatomical coregistration.
To determine temporal changes of tracer concentration in var-
ious tissues, ellipsoid regions of interest were placed in the region
that exhibited the highest 64Cu activity as determined by visual
inspection. To ensure accurate anatomical positioning, regions of
interest were placed on fused micro-PET/CT images generated by
theAMIDE software (17). Tominimize partial volume effects, care
was taken not to include the anatomical borders of the organs.
Considering the size of the studied organs and tumors and the
spatial resolution of the PET scanner, partial volume effects are not
expected to have a major impact on the results of quantitative
analysis. Activity concentrations are expressed as percent of the
decay-corrected injected activity per cm3 of tissue (can be approx-
imated as percentage ID/g), using the AMIDE software, and these
values are normalized to an elliptic cylinder region of interest drawn
over the entire mouse. Blood activities represent the whole blood
volume, so plasma concentrations are 2-fold greater, assuming
50% hematocrit.
BLI. BLI was performed by using a Xenogen IVIS 100 imaging
system. Mice were anesthetized with 2.5% isoflurane and injected
i.p. with 0.2 ml of a 15 g/liter D-luciferin solution in PBS. Light
emission was measured 10 min after injection of the D-luciferin
solution, and bioluminescent signals were quantified by usingLiving
Image software (Xenogen).
Compartmental Modeling.A three-compartment model was used to
investigate the impact of tumor-specific targeting on tumor accu-
mulation. Model variables and parameters are defined in Tables 1
and 2. The system of first-order ODEs was solved by using
MATLAB (Mathworks, Natick, MA).
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